Arax Advisory Partners’s Humacyte HUMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.9K Sell
7,535
-34,364
-82% -$22K ﹤0.01% 4756
2026
Q2
$32.7K Buy
41,899
+37,779
+917% +$35K ﹤0.01% 3610
2026
Q1
$2.5K Sell
4,120
-893
-18% -$928 ﹤0.01% 3040
2025
Q4
$4.82K Sell
5,013
-4,369
-47% -$6.19K ﹤0.01% 2878
2025
Q3
$16.3K Buy
9,382
+8,382
+838% +$16.4K ﹤0.01% 2369
2025
Q2
$2.09K Hold
1,000
– – ﹤0.01% 2557
2025
Q1
$1.7K Sell
1,000
-473
-32% -$1.78K ﹤0.01% 2116
2024
Q4
$7.44K Sell
1,473
-84
-5% -$416 ﹤0.01% 1593
2024
Q3
$8.47K Buy
1,557
+774
+99% +$5.1K ﹤0.01% 1489
2024
Q2
$3.76K Buy
+783
New +$4.08K ﹤0.01% 1714

Other funds holding HUMA

Arax Advisory Partners's HUMA Position: Q3 2026 in Review

Arax Advisory Partners reduced its Humacyte (HUMA) stake by 82% in Q3 2026, selling an estimated $22K and leaving 7,535 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4756.

Arax Advisory Partners first reported a position in HUMA in Q2 2024 and has held it in 10 quarters since. The position peaked at $32.7K in Q2 2026. 130 funds tracked by Wall St. Rank hold HUMA as of Q3 2026.

  • Arax Advisory Partners held 7,535 shares of Humacyte worth $3.9K as of Q3 2026.
  • Arax Advisory Partners sold 34,364 Humacyte shares in Q3 2026, an estimated $22K.
  • Humacyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4756 holding.
  • Arax Advisory Partners first reported a position in Humacyte in Q2 2024 and has held it in 10 quarters since.
  • Arax Advisory Partners's Humacyte position peaked at $32.7K in Q2 2026.
  • 130 funds tracked by Wall St. Rank held Humacyte as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.